Testimony Before the FDA’s Cardiovascular and Renal Drugs Advisory Committee Regarding Daprodustat for the Treatment of Anemia Due to Chronic Kidney Disease
View complete testimony as PDF
In testimony before the Food and Drug Administration’s (FDA’s) Cardiovascular and Renal Drugs Advisory Committee, Public Citizen urged the committee to recommend that the FDA not approve daprodustat for treatment of anemia due to chronic kidney disease in adult patients not on dialysis or on dialysis because the drug offers no unique benefits compared to earlier FDA-approved erythropoiesis-stimulating agents but does have greater risks of serious adverse events.